

CLAIMS

1. Use of metronidazole for the preparation of a pharmaceutical composition for treating a cutaneous vascularization disorder.
2. Use according to Claim 1, characterized in that the said cutaneous vascular disorder involves at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
3. Use according to Claim 1 or 2, characterized in that the said cutaneous vascular disorder involves at least two receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
4. Use according to any one of Claims 1 to 3, characterized in that the said cutaneous vascular disorder involves at least three receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
5. Use according to any one of Claims 1 to 4, characterized in that the said cutaneous vascular disorder involves at least four receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
6. Use of metronidazole according to any one of Claims 1 to 5, characterized in that the said cutaneous vascular disorder involves at least five receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

7. Use according to Claim 1, characterized in that the said vascular disorder is a component of rosacea and in that metronidazole is capable of interacting with at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 10 8. Use according to any one of Claims 1 to 7, characterized in that metronidazole inhibits the binding of at least one natural ligand to its receptor, the said receptor being chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 15 9. Use according to any one of Claims 1 to 8, characterized in that the said pharmaceutical composition is a dermatological composition for topical application.
- 20 10. Use according to any one of Claims 1 to 9, characterized in that the composition is for treating at least one stage of rosacea.
- 25 11. Use according to any one of Claims 1 to 10, characterized in that the composition is for treating the first stage of rosacea.
- 30 12. Use according to any one of Claims 1 to 11, characterized in that the composition is for treating the second stage of rosacea.
- 35 13. Use according to any one of Claims 1 to 12, characterized in that the composition is for treating the third stage of rosacea.
14. Use according to any one of Claims 1 to 13,

characterized in that the composition is for treating the fourth stage of rosacea.

- 5 15. Use according to any one of Claims 1 to 14, characterized in that the said composition contains from 0.0001% to 20% by weight, preferably from 0.1% to 2%, and more preferentially from about 0.75% to 1% by weight of metronidazole.
- 10 16. Use according to any one of Claims 1 to 15, characterized in that the said composition also contains another active agent chosen from the group of antibiotics, antibacterial agents, antiviral agents, anti-parasitic agents, antifungal agents, anaesthetics, 15 analgesics, anti-allergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, keratolytic agents, anti-seborrhoeic agents, antihistamines, sulfides, immunosuppressant products and anti-proliferative products.
- 20 17. Use according to any one of Claims 1 to 16, characterized in that the composition contains an additive chosen from the group of sequestrants, 25 antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, colorants common mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, skin calmateive and protective agents, pro- 30 penetrating agents and gelling agents, or a mixture thereof.